Advanced Search

Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2006 June;141(3) > Giornale Italiano di Dermatologia e Venereologia 2006 June;141(3):207-14



A Journal on Dermatology and Sexually Transmitted Diseases

Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

Frequency: Bi-Monthly

ISSN 0392-0488

Online ISSN 1827-1820


Giornale Italiano di Dermatologia e Venereologia 2006 June;141(3):207-14


Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria

Seidenari S. 1, Cirillo A. 1, Amoroso S. 3, Flori M. L. 4, Amerio P. 5, Ricciuti E. 6, Vena G. A. 7, Berardesca E. 8, Le Grazie C. 9 e il Gruppo di Studio Italiano sulla Desloratadina (DL) nell’Orticaria Cronica*

1 Department of Dermatology, Polyclinic, Modena, Italy
2 Allergology Unit, Civic Hospital, Caserta, Italy
3 Allergology Unit Civic and Benfratelli Hospital, Palermo, Italy
4 Department of Dermatology A.O. Senese (Hospital), Siena, Italy
5 Department of Dermatology Gemelli Polyclinic, Rome, Italy
6 Dermatology Unit, Carlo Hospital, Potenza, Italy
7 Department of Dermatology Policlinico Consorziale Hospital, Bari, Italy
8 Dermatology Institute, IRCCS San Gallicano, Rome, Italy
9 Medical Department, Schering Plough Spa, Milan, Italy

Aim. Desloratadine (DL) is an effective treatment for chronic idiopathic urticaria (CIU) symptoms, but there is little information about its impact on patients’ perceived general wellbeing. The primary objective was to measure the effect of DL on the quality of life (QoL) of CIU patients, using the Dermatology Life Quality Index (DLQI). Secondary objectives were: evaluation of the effects of DL on pruritus and number of hives, sleep and daily activities, overall CIU condition, and assessment of therapeutic response. Safety and tolerability of DL were also evaluated.
Methods. Two-hundred and fifty-five patients, aged 18-79 years and with moderate to severe CIU, were treated with DL 5 mg once daily for 28 days. Patients recorded signs and symptoms scores daily, and completed the DLQI questionnaire at baseline and on treatment days 7, 14, 21 and 28. Patients and investigators jointly evaluated overall CIU condition and therapeutic response at days 14 and 28.
Results. After 28 days of treatment, DL significantly reduced mean overall DLQI score from 9.4 (±5.4) at baseline to 3 (±4.1) (–66.1%; P<0.001), with no significant differences between moderate and severe patients. Improvement in QoL was significant (P<0.001) at all time points and for all DLQI domains. All signs and symptoms scores were significantly correlated with DLQI score.
Conclusion. Treatment with DL 5 mg for 4 weeks significantly improves symptoms and QoL in patients with CIU, irrespective of disease severity, and with a rapid onset of action.

language: English


top of page